Taken together, our results suggest that the administration of the PPAR pan agonist effectively prevented renal fibrosis in both in vitro and in vivo models of kidney fibrosis, implicating the therapeutic potential of PPAR agonists against chronic kidney diseases (Figure 7). The gene discussed is PPARA; the disease is chronic kidney disease.